Neuburgh Advisers LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 188,672 shares of the medical research company’s stock after selling 5,324 shares during the period. Thermo Fisher Scientific accounts for approximately 1.3% of Neuburgh Advisers LLC’s investment portfolio, making the stock its 17th biggest holding. Neuburgh Advisers LLC’s holdings in Thermo Fisher Scientific were worth $39,082,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Pitcairn Co. lifted its holdings in Thermo Fisher Scientific by 1.3% in the 2nd quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock worth $3,495,000 after purchasing an additional 215 shares during the last quarter. Front Row Advisors LLC lifted its holdings in Thermo Fisher Scientific by 4.0% in the 1st quarter. Front Row Advisors LLC now owns 6,049 shares of the medical research company’s stock worth $1,249,000 after purchasing an additional 234 shares during the last quarter. Nvwm LLC lifted its holdings in Thermo Fisher Scientific by 6.1% in the 2nd quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock worth $877,000 after purchasing an additional 242 shares during the last quarter. Chesapeake Wealth Management lifted its holdings in Thermo Fisher Scientific by 6.0% in the 2nd quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock worth $910,000 after purchasing an additional 249 shares during the last quarter. Finally, Middleton & Co Inc MA lifted its holdings in Thermo Fisher Scientific by 2.4% in the 2nd quarter. Middleton & Co Inc MA now owns 10,873 shares of the medical research company’s stock worth $2,252,000 after purchasing an additional 253 shares during the last quarter. Institutional investors and hedge funds own 85.93% of the company’s stock.

Several research firms recently weighed in on TMO. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. Leerink Swann boosted their target price on Thermo Fisher Scientific from $239.00 to $255.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Morgan Stanley lifted their price target on Thermo Fisher Scientific from $233.00 to $242.00 and gave the stock an “overweight” rating in a research report on Thursday, July 26th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $300.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 26th. Finally, ValuEngine raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Tuesday, July 24th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $239.08.

Shares of NYSE TMO opened at $239.19 on Friday. The company has a current ratio of 1.58, a quick ratio of 1.11 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $95.85 billion, a price-to-earnings ratio of 25.20, a price-to-earnings-growth ratio of 1.73 and a beta of 1.13. Thermo Fisher Scientific Inc. has a 12 month low of $177.29 and a 12 month high of $240.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 25th. The medical research company reported $2.75 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.63 by $0.12. The company had revenue of $6.08 billion for the quarter, compared to the consensus estimate of $5.90 billion. Thermo Fisher Scientific had a return on equity of 16.28% and a net margin of 10.36%. The company’s revenue for the quarter was up 21.8% on a year-over-year basis. During the same period in the previous year, the business posted $2.30 EPS. research analysts forecast that Thermo Fisher Scientific Inc. will post 10.98 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 15th. Shareholders of record on Monday, September 17th will be given a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Friday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

In other news, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 4th. The stock was sold at an average price of $212.00, for a total transaction of $530,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $214.80, for a total value of $9,666,000.00. Following the sale, the chief executive officer now owns 315,122 shares in the company, valued at $67,688,205.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 168,050 shares of company stock worth $37,585,029. Company insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Further Reading: Market Capitalization and Individual Investors

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.